12:00 AM
May 24, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Remicade infliximab: Marketed to treat adults with severe Crohn's disease not treatable with conventional therapy

Researchers presented data from 12 patients 11-17 years old showing that 5 patients went into remission at some time during the first...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >